This is both an opportunity and a challenge for Zhongshan.
After years of cultivation and development, Zhongshan biomedical industry has emerged. In June, many good news came from the National Health Base of Zhongshan Torch Development Zone. First, Benvimod Cream (trade name: Hinbik), the world's first drug with independent intellectual property rights developed by Guangdong Zhonghao Pharmaceutical Co., Ltd., went on the market after passing the priority review and approval procedure by the State Administration of Pharmaceutical Products, which is a landmark achievement of China's leading international in this field. On June 2 1 day, Kangfang Biomedical Co., Ltd. (hereinafter referred to as "Kangfang Bio") won the "Outstanding Biomedical Enterprise Award" for its innovative research and development platform and assembly line of bifunctional antibody products in tumor immunotherapy.
The Outline of Guangdong-Hong Kong-Macao Greater Bay Area Development Plan puts forward "supporting Zhongshan to promote biomedical science and technology innovation". Biomedical industry, as a key emerging industry in Zhongshan, has accumulated a certain industrial base. Compared with Hong Kong, Macao and Taiwan, Guangzhou and Shenzhen, how does Zhongshan, which lacks a "big courtyard and big office", develop its strengths and avoid its weaknesses and find its place in the biomedical industry chain of Greater Bay Area?
Industrial distribution
From "One Base" to Trilateral Struggle
Looking back at the interaction between Zhongshan and Hong Kong and Macao since last year, one detail is intriguing.
In March and June of 20 18, following the visit to key enterprises, universities and science and technology bases in Hong Kong and Macao by Zhongshan delegation led by the main leaders of Zhongshan city in early 20 18, Carrie Lam Cheng Yuet-ngor, Chief Executive of Hong Kong Special Administrative Region, and Chui Sai On, Chief Executive of Macao Special Administrative Region visited Zhongshan successively.
It is worth noting that both Carrie Lam Cheng Yuet-ngor and Chui Sai On chose Zhongshan National Health Base as one of the important inspection sites, and conducted in-depth exchanges with enterprises in the health base.
Then, in July, 2065438+2008, Zhongshan Summit on the Innovation and Development of Biomedical Industry in Guangdong-Hong Kong-Macao Greater Bay Area was held in Zhongshan, and "Guangdong Pharmaceutical University-HKU Innovation Platform" was settled in Zhongshan National Health Base.
There are indications that Zhongshan health medicine industry is ahead in cooperation with Hong Kong and Macao.
The large-scale development track of Zhongshan biomedicine can be traced back to more than 20 years ago. 1994 The Ministry of Science and Technology, the Guangdong Provincial People's Government and the Zhongshan Municipal People's Government jointly established the National Health Science and Technology Industrial Base, and selected the Torch Development Zone. It is the first national comprehensive health industrial park built in China according to internationally recognized standards of GLP, GCP, GMP and GSP, with a total planned area of 13.5 square kilometers. After years of development, more than 300 enterprises have gathered, forming an industrial cluster pattern of coordinated development of biomedicine, medical equipment, wisdom and health, health food and cosmetics. It is the first batch of innovative industrial cluster pilot parks in China, the national demonstration base of new industrialized industries, the national modern service industry digital medical industrialization base, and the national science and technology business incubator.
Relying on a platform with a high starting point, the industry has made great progress. A landmark event that can better reflect the status of Zhongshan's health medicine industry is that the Wu Jieping Prize for Medicine, the highest award in the field of medicine and health in China, has been held in Zhongshan for 10.
High-end summits are held in Zhongshan more and more frequently. In April this year, Guangdong-Hong Kong-Macao Greater Bay Area Zhongshan Biomedical Industry Summit Forum was held in Cuiheng New District, Zhongshan, which also released another signal: the layout of biomedical industry has become an important construction content of Cuiheng New District, the frontier of Zhongshan's participation in Guangdong-Hong Kong-Macao Greater Bay Area's construction. This can also be seen from the specifications of the forum: this forum invited nearly 60 experts and scholars from the Institute of Pharmaceutical Innovation of Chinese Academy of Sciences, HKUST and other well-known institutions, research institutes and universities and representatives from the State Key Laboratory of Pharmacy to participate in the strategic research on the development of biomedical industry in Zhongshan and even Guangdong-Hong Kong-Macao Greater Bay Area, and plan the future development layout.
With the establishment of Zhongshan Research Institute (South China Branch) of Institute of Drug Innovation of China Academy of Sciences in Cuiheng New District and the promotion of the construction of Sino-German (Zhongshan) Biomedical Industrial Park, the layout of Zhongshan Biomedical Industry has completed the full coverage of the eastern cluster towns: Torch National Health Science and Technology Industrial Base, Cuiheng New District Biomedical Science and Technology Park and nanlang town South China Modern Chinese Medicine City. Among them, the Torch District National Health Science and Technology Industrial Base focuses on the development of biomedicine, innovative research and development of medical devices and accelerated incubation, and the integration of new generation information technology and health medicine industry, supporting its expansion to towns and villages such as the people and enhancing the space for industrial development; Cuiheng New District Biomedical Science and Technology Park focuses on the development of innovative R&D and industrialization projects in the fields of biopharmaceuticals, medical devices and pharmaceutical equipment, and builds high-level innovation platforms and research institutions relying on scientific research institutes in universities; Nanlang town South China Modern Chinese Medicine City focuses on the development of modern Chinese medicine, biological health products, medical devices and other fields.
development trends
Cooperate with Guangzhou, Shenzhen, Hong Kong and Macao.
From Torch Development Zone to Cuiheng New District, the "eastward development" of health medicine is also a strong signal of collaborative innovation to the cities on the east coast of the Pearl River.
The cooperation between Zhongshan and Hong Kong and Macao health industry has a long history. At present, a number of Hong Kong-funded enterprises, such as Federal Pharmaceutical, Yabo Pharmaceutical, Xinyikang Biotechnology, Eurasian Packaging and Qitai Pieces, have settled down, making important contributions to the economic development of Zhongshan. Besides, Shenqi Oral Liquid and Shi Qi Waigan Granules of Zhongzhi Pharmaceutical Group, a local chain pharmacy in Zhongshan, have also completed the standard registration of Chinese patent medicines in Hong Kong. At present, more than 65,438+00 pieces of broken pieces have been registered in Hong Kong for food export.
20 17 Jincheng pharmaceutical, an enterprise in the health base industrial park, signed a contract with Italian multinational companies and Hong Kong Liwei International to build a cephalosporin reference preparation research and high-quality cephalosporin preparation industrialization base in the core area of Sino-German (Zhongshan) Biomedical Industrial Park.
Under the planning background of Guangdong-Hong Kong-Macao Greater Bay Area, the idea of creating a national biomedical science and technology innovation zone by cooperation between Zhongshan and Hongkong has also attracted the attention of both sides. As far as Zhongshan is concerned, Hong Kong's medical supervision system and mechanism, the function of a free port and the role of being in line with international standards have advantages because of its policy of striving for global simultaneous application of innovative drugs and the pioneering research and application of cutting-edge medical technologies such as cellular immunotherapy. Taking advantage of Zhongshan's industrial base and Hong Kong's resource advantages, the Innovation Zone can be built into a world-class biomedical R&D cluster, an international biomedical industrial base, a world-class high-end medical science and technology service cluster, a demonstration base for deepening cooperation and innovation, and a high-level international exchange and cooperation platform in the health field. According to the plan, Zhongshan Health Base will also actively connect with high-end innovative resources such as "State Key Laboratory of Biomedicine" of Hong Kong University and Hong Kong Science and Technology Park, and rely on Zhongshan Incubation Accelerator and Industrial Park to realize technological transformation.
At the same time, scientific research cooperation with Guangzhou and Shenzhen in the field of biomedicine has also been significantly accelerated.
In terms of cooperation with Guangzhou universities, the interaction with Guangdong Pharmaceutical University is the most typical. According to the Agreement between Guangdong Provincial Department of Education and Zhongshan Municipal People's Government on the Construction of Zhongshan Campus of Guangdong Pharmaceutical University, Guangdong Provincial Department of Education and Zhongshan Municipal Government approved the overall plan for the joint construction of Guangdong Pharmaceutical University between provinces and cities. According to the plan, the Guangdong Provincial Department of Education and Zhongshan Municipal Government will focus on supporting Guangdong Pharmaceutical University, Hong Kong University and Zhongshan to jointly establish new research and development institutions (technology business incubators and technology transfer centers) and Zhongshan Branch of the State Key Laboratory of Biomedicine.
In terms of docking with Shenzhen, Cuiheng New District, which has geographical advantages, is one step ahead-introducing Shenzhen Medical Device Industrial Park as a whole.
This project is jointly carried out by Shenzhen Medical Device Industry Association and Zhongshan National Health Base. According to the relevant person in charge, the total investment of the project is 654.38+0.46 billion yuan. This industrial park, covering an area of 283 mu, has been included in the key project of "Advanced Equipment Manufacturing on the West Coast of the Pearl River" in Guangdong Province. At present, it has been introduced into South China Branch of Shanghai Institute of Pharmacology, China Academy of Sciences. According to the plan, Cuiheng New District will build a Industry-University-Research platform for drug clinical research, drug safety evaluation, drug research and development, and macromolecular drugs.
There are indications that Zhongshan biomedical industry has ushered in a new stage of development.
■ sample
"Innovative Medicine" Going Abroad from National Health Base
In March this year, Zhongshan Kangfang Biomedical Co., Ltd. (hereinafter referred to as "Kangfang Bio") announced that its subsidiary Kangfang Pharmaceutical Co., Ltd. launched Ib/II clinical trials in China with a new bispecific antibody AK1/CTLA-4.
"This is another major milestone of the AK 104 project after the completion of the Australian phase Ia clinical trial." Yu Xia, Chairman, President and CEO of Kangfang Bio, said, "In the future, Kangfang Bio will also launch a number of clinical studies on AK 104 single drugs and AK 104 combined drugs for various malignant tumors, so that cancer patients around the world can get good drugs made in China." It is reported that this is the first double antibody product independently developed by Kangfang Bio using Kangfang's unique four-antibody double antibody platform, and it is also the first PD- 1/CTLA-4 bispecific antibody in the world to enter clinical trials.
As a biopharmaceutical company located in Zhongshan, a national health base, Kangfang Bio's most well-known "achievement" in the industry is the monoclonal antibody drug AK- 107 developed by the company, which was once bought by the international giant Merck. 20 15 1 1 month, Kangfang Bio and Merck, headquartered in New Jersey, new york Bay Area, USA, reached a cooperation on the development and promotion of a monoclonal antibody drug AK 107 for tumor immunotherapy. This immune checkpoint, discovered by Kangfang Bio in China and used for tumor immunotherapy, will block antibodies, Merck will gain its exclusive right to develop and promote globally, and Kangfang Bio will receive an advance payment and an installment payment with a total price of 200 million US dollars covering development and promotion. This breakthrough also provides a reference path for domestic pharmaceutical companies and start-ups to get out of the "outsourcing fence".
China Innovation Biotechnology Co., Ltd. authorized the new monoclonal antibody drug independently developed to the five major pharmaceutical giants in the world. Kangfang Bio's move was regarded by the industry as "a new breakthrough of domestic innovative drugs in overseas markets". Zhang Peng, vice president and chief operating officer of Kangfang Bio, said that the growth and development of Kangfang Bio cannot be separated from the international technology docking and cooperation vision: "Continue to cooperate with domestic and foreign pharmaceutical companies in various forms, and * * * will quickly introduce new antibody drugs independently developed from the drug discovery stage to the market."
"The road to innovation based on internationalization is the direction that Kangfang Bio has always adhered to." Since obtaining the 300 million yuan Series B financing, Kangfang Bio has mainly promoted the clinical application of new drugs and site selection and production. In the field of subsequent production line design and equipment, the advanced experience of biopharmaceuticals in San Francisco Bay Area and new york Bay Area will be used for reference by Kangfang Bio.
■ observation
From industrial agglomeration to innovation leading;
Break through the shortcomings of industrial development.
Health medicine industry is the dominant industry in Zhongshan. Since 1994 Zhongshan was approved to build the first national health science and technology industrial base, relying on the platform with a high starting point, the industry has made great progress. A landmark event that can better reflect the status of Zhongshan's health medicine industry is that the Wu Jieping Prize for Medicine, the highest award in the field of medicine and health in China, has been held in Zhongshan for 10.
However, another unavoidable fact is that the existing innovation platforms in Zhongshan, including health medicine industry, are not high in level, and most of them are established by enterprises, which are oriented by technology application and development, and their original innovation ability is weak. In terms of carrier construction and enterprise agglomeration effect, Zhongshan already has national and provincial industrial parks such as National Health Science and Technology Industrial Base and South China Modern Chinese Medicine City, and has also established an industrial innovation and service system covering R&D, pilot test, inspection and testing, achievement transformation and other processes, and gathered key enterprises such as Novartis Sandoz, Federal Pharmaceutical, Kangfang Bio and Mingfeng Medical, forming an industrial cluster covering biopharmaceuticals, chemicals, modern Chinese medicine and medical devices.
According to statistics, in 20 17, the output value of health medicine in Zhongshan city was about 80 billion yuan, which is still far from the "100 billion" industrial cluster. According to "Zhongshan Health Medicine Industry Development Action Plan (20 18-2022)" issued by Zhongshan City in August, 2018, by 2022, the city's health medicine industry scale will reach 120 billion yuan, and the output value will increase by 50% compared with 20 17.
To achieve such a leap, the industrial development model oriented by technology application and development is obviously relatively weak. Especially since Zhongshan implemented the collectivization development strategy, the eastern delegations including Torch Development Zone, Cuiheng New District and nanlang town all focused on health care. Then, in the new round of development, how to realize the industrial map from "quantitative change" to "qualitative change", the core scientific and technological innovation ability must obviously keep up.
Judging from the industrial development track of the World Bay Area, the health medicine industry is one of the most important industries of the government, whether in the New York metropolitan area or the San Francisco Bay Area. For example, New Jersey has a strong health medicine industry in the United States, and is the representative of the eastern new york Bay Area, mainly developing mature pharmaceutical companies and medical device companies. More than 65,438+000 Fortune 500 companies have set up factories or branches in middlesex, among which New Brunswick is called a "healthy city". Driven by leading enterprises, the city's health medicine industry has developed, giving birth to a large number of small and medium-sized enterprises supporting the industry. The tertiary industry developed around health care is developed, and at the same time, it has strong scientific research and innovation strength-Rutgers University is located at the northern end of the "high-tech corridor" in expressway, USA 1, while Princeton University is at the southern end of this corridor, and its universities and scientific research institutions are at the leading level in many fields. Auckland, located in the northeast of the San Francisco Bay Area, has also formed a certain scale in its health medicine industry. Many of these biotechnology companies originated in Silicon Valley, and the innovation core has obvious radiation driving effect on the surrounding areas.
The enlightenment that these Bay Area cities can bring to Zhongshan is that, besides introducing enterprises, building a technology transformation platform and building a solid industrial foundation such as health medicine, there is another dimension worthy of attention: introducing universities and research institutes with top rankings in related professional fields at home and abroad, cooperating to build laboratories and technological innovation platforms in Zhongshan, gathering leading talents from academia and industry to carry out collaborative innovation, and promoting the latest and cutting-edge research papers in the industry to be transformed into new technologies, new materials and new processes to improve products.
Judging from the current development trend of biomedical industry in Zhongshan, relying on the national health base, there is a trend of continuous eastward expansion: inward, Sino-German (Zhongshan) Biomedical Industrial Park and Shenzhen Medical Device Industrial Park will be laid out in Cuiheng New District, and nanlang town will develop South China Modern Chinese Medicine City and other industrial platforms for common development; Externally, actively connect biomedical R&D institutions and industries in Hong Kong, Macao, Guangzhou and Shenzhen, seek new paths for collaborative innovation and development, and undertake the transformation of achievements.
The "eastward shift" layout of Zhongshan biomedical industry aims to form a biomedical all-factor innovation chain integrating scientific research, innovative research and development, pilot transformation, final assembly testing, clinical trials and demonstration and promotion. This will provide more powerful support for the East Zhongshan Group, which is deeply integrated into the Pearl River Estuary, to build a complete industrial chain with biomedicine as the leading industry, scientific research and development as the core and achievements transformation as the core.
■ Outlook
Gather "small but alive" enterprises
It can bring opportunities for the dislocation development of Zhongshan.
Although the biomedical industry in Zhongshan has made great progress, and from the current key industries and policy support in Zhongshan, it is a new growth point with high hopes: "Zhongshan Health Medicine Industry Development Action Plan (20 18-2022)" proposes that by 2022, the total output value of Zhongshan Health Medicine Industry will reach12 billion yuan.
It is expected to become the next 100 billion-level emerging industry in Zhongshan. What is the current situation of biomedical industry in Greater Bay Area? What are the opportunities for Zhongshan to bid for Hong Kong, Macao, Guangzhou and Shenzhen? What is the most critical development factor in this opportunity?
Undoubtedly, Zhongshan biomedical industry is facing new opportunities. However, in terms of scale, volume and innovation ability, Zhongshan is still weak compared with Hong Kong, Guangzhou, Shenzhen and other cities on the east coast of the Pearl River.
From the industrial characteristics, Shenzhen and Guangzhou have obvious advantages in clinical diagnosis, innovative drugs, cell therapy and other fields, while Zhongshan is currently involved in the research and development of antibody drugs and high-end medical equipment in protein, but the foundation is far less than that of Guangzhou and Shenzhen.
"On the one hand, it is related to industrial accumulation, on the other hand, it is also related to the supporting role of innovative resources such as universities." Hu, deputy general manager of Guangdong Zhonghao Pharmaceutical Co., Ltd. said that Zhongshan can start with the transformation of achievements, introduce "small but alive" high-growth companies, and stimulate the industrial agglomeration effect of biomedicine.
Zhang Peng, vice president and chief operating officer of Kangfang Bio, holds the same view. He believes that the opportunity of Zhongshan biomedical industry lies in gathering more innovative enterprises. In this process, it is the most critical to use the advantages of policy, location and supporting facilities to realize the agglomeration of innovative resources.
This view has also been recognized by Reation Wu, co-founder and vice president of Kang Sheng Bio. He believes that Zhongshan can't compare with Hong Kong, Guangzhou, Shenzhen and other cities on the east bank of the Pearl River in terms of volume, scale and innovation ability, but Zhongshan can start from introducing high-growth enterprises and gather the upstream and downstream industries of the health medicine industry, thus "rising".
Zhang Peng believes that the development model of biomedicine in Jiangsu and Shanghai can provide experience for Zhongshan, that is, relying on the innovative resources of first-tier cities to introduce a large number of high-growth innovative enterprises. Its biggest feature is that there are many innovative enterprises with small scale, but with high technology content, rapid growth and great potential. "If such enterprises emerge in Zhongshan, the atmosphere of innovation will be basically cultivated, and more and more elements will gather here."
Kangfang Bio itself is a typical innovative enterprise. Several people with the same idea started their own businesses, used their own advantages and technical background to carry out international operations, and achieved rapid growth after the A and B rounds of financing. This company ranks among the leading innovative biopharmaceutical enterprises in China in just a few years. Zhang Peng believes that there are several important factors. The first is "someone": several entrepreneurial backbones have rich experience and are very familiar with international cutting-edge technologies, R&D trends and industry trends. With R&D and management talents, if everyone has the same goal, it will be easy to do it. The second is "project". Everyone has participated in the research and development and management of some large international pharmaceutical companies in Europe and America before, and has a precise grasp of the market. The starting point of choice is also relatively high, that is, insisting on being an innovative biopharmaceutical company.
Judging from the development experience of Guangzhou-Shenzhen biomedicine in Hong Kong and Macao, university resources are a great support. In the final analysis, talents can not only bring technological updates, but also bring industrial updates. For the government, the policy bonus is not only financial support, but also a very important point, such as giving space, giving preferential treatment, making good plans, improving supporting facilities and selecting projects. The development of biomedical industry needs to be clearly defined, policies should be introduced in the process of industrial planning, high-quality projects should be introduced, and the development of innovative enterprises with potential should be supported. In this way, after the atmosphere of innovation is strong, the soil of innovation will also settle down and provide nutrients for industrial agglomeration.